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A B S T R A C T
Background: The impact of HLA-DP mismatches on renal allograft outcome is still poorly understood and is
suggested to be less than that of the other HLA loci. The common association of HLA-DP donor-specific anti-
bodies (DSA) with other DSA obviates the evaluation of the actual effect of HLA-DP DSA.
Methods: From a large multicenter data collection, we retrospectively evaluated the significance of HLA-DP
DSA on transplant outcome and the immunogenicity of HLA-DP eplet mismatches with respect to the induction
of HLA-DP DSA. Furthermore, we evaluated the association between the MFI of HLA-DP antibodies detected in
Luminex assays and the outcome of flowcytometric/complement-dependent cytotoxicity (CDC) crossmatches.
Results: In patients with isolated pretransplant HLA-DP antibodies (N=13), 6 experienced antibody-
mediated rejection (AMR) and 3 patients lost their graft. In HLAMatchmaker analysis of HLA-DP mismatches
(N=72), HLA-DP DSA developed after cessation of immunosuppression in all cases with 84DEAV (N=14), in
86% of cases with 85GPM (N=6/7), in 50% of cases with 56E (N=6/12) and in 40% of cases with 56A
mismatch (N=2/5). Correlation analysis between isolated HLA-DP DSA MFI and crossmatches (N=90)
showed negative crossmatch results with HLA-DP DSA MFI <2000 (N=14). Below an MFI of 10,000 CDC
crossmatches were also negative (N=33). Above these MFI values both positive (N=35) and negative
(N=16) crossmatch results were generated.
Conclusions: Isolated HLA-DP DSA are rare, yet constitute a significant risk for AMR. We identified high-risk
eplet mismatches that can lead to HLA-DP DSA formation. We therefore recommend HLA-DP typing to perform
HLA-DP DSA analysis before transplantation. HLA-DP DSA with high MFI were not always correlated with
positive crossmatch results.
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1. Introduction
The HLA disparity between donor and recipient determines the
immunogenicity of an allograft and consequently has an impact on the
outcome after kidney transplantation [1]. In the Eurotransplant region,
HLA-A, -B, -C, -DR, -DQ antigens and antibodies are entered into the
Eurotransplant Network Information System (ENIS) and used for the
allocation of solid organs whereas HLA-DP typing is not routinely
performed. As a consequence, little is known about the impact of HLA-
DP mismatches (MM) and antibodies on outcome, despite the high
probability that a donor is mismatched for HLA-DP, even if a donor-
recipient pair is identical at all classical loci [2,3].
HLA-DP is an HLA class II molecule identified more than 40 years
ago, composed of 2 chains, DPα and DPβ, which are respectively en-
coded by the polymorphic DPA1 and DPB1 locus. At present, 1449 HLA-
DPB1 and 132 HLA-DPA1 alleles have been reported (IPD-IMGT/HLA
Database release 3.37.0, June 2019). The polymorphism of HLA-DPB1
is largely concentrated in six hypervariable regions (HVRs), A-F, in
exon 2 of the HLA-DPB1 gene. HLA-DPA1 is less polymorphic and di-
vided into four groups: DPA1*01 – DPA1*04. Notwithstanding the
heterogeneity in the HLA-DP molecules, HLA-DP has been considered to
be less immunogenic than other HLA antigens, because of the low ex-
pression of HLA-DP on renal endothelium [4–12].
Since the introduction of the Luminex Single Antigen Bead assay
15 years ago, anti-HLA-DP antibodies are easily detected, providing the
option to evaluate their clinical relevance. But in most cases, it is dif-
ficult to dissect the importance of HLA-DP donor-specific antibodies
(DSA) as they are often accompanied by other DSA, especially DSA
against HLA-DQ, which are well known to be associated with impaired
graft survival [3].
1.1. Objective
To evaluate the clinical significance of HLA-DP mismatches and DSA
in kidney transplantation, we addressed three questions in our retro-
spective case series. Firstly, we investigated the clinical outcome of
patients with isolated HLA-DP DSA. Secondly, we assessed the asso-
ciation between specific eplet mismatches and the risk of developing
donor-specific HLA-DP antibodies after a failed kidney graft. Thirdly,
we evaluated the association between the MFI of HLA-DP antibodies
detected in Luminex assays and the outcome of flowcytometric (FCXM)
and complement-dependent cytotoxicity (CDC-XM) crossmatches.
2. Materials and methods
2.1. Case series identification and data collection
We performed this analysis in the HLA laboratory of Red Cross-
Flanders (Histocompatibility and Immunogenetics Laboratory (HILA),
Mechelen, Belgium) which is the only European Federation for
Immunogenetics (EFI) accredited HLA laboratory for organ transplanta-
tion in the Flanders region of Belgium. This HLA laboratory provides
services for the kidney transplantation centers of the Antwerp University
Hospital, the Ghent University Hospital and the University Hospitals
Leuven. To evaluate the clinical significance of HLA-DP mismatches and
DSA in kidney transplantation, we addressed three questions in our ret-
rospective case series and an overview is shown in Fig. 1.
Firstly, to investigate the clinical outcome of HLA-DP antibodies in
kidney transplantation, we screened our laboratory information system
for the period 2008 to 2018 for kidney transplant patients (N=1736)
and only included patients with isolated HLA-DP DSA, analyzed post-
transplant in the period between 2008 and 2018. Additional require-
ments for inclusion were the availability of both patient and donor
HLA-DP typing for correct interpretation of the HLA-DP antibody pro-
file with HLAMatchmaker eplet analysis and histologic evaluation of
biopsies on the basis of the Banff criteria. A total of 14 patients met
these inclusion criteria (Fig. 1, 1st cohort).
In order to assess the association between specific eplet mismatches
and the risk of developing donor specific HLA-DP antibodies after a
failed kidney graft, we included a multicenter cohort of kidney trans-
plant patients with a failed kidney graft, who returned on the waiting
list in 2008–2018 (N=497). We specifically selected retransplant
candidates as patients receive maintenance immunosuppression during
post-transplant follow-up, which may interfere with DSA formation and
correct interpretation of the data to address our second question on the
incidence of HLA-DP DSA. HLA-DP typing of both patient and donor
was mandatory to analyze the immunogenicity of specific HLA-DP eplet
mismatches. Another inclusion criterion was a negative pre-transplant
HLA-class II antibody screening because pre-existing HLA antibodies
could interfere in such immunogenicity studies. We included a total of
72 patients in this analysis (Fig. 1, 2nd cohort).
Thirdly, we evaluated the association between the MFI of HLA-DP
antibodies detected in Luminex assays and the outcome of FCXM and
CDC-XM on retrospective data and on crossmatch results with historical
sera of patients with isolated HLA-DP DSA. We evaluated in total 55 CDC-
XM (25 different donors and 42 different sera) and 35 FCXM (19 different
donors and 10 different sera) results in this analysis (Fig. 1, 3rd cohort).
We retrospectively collected clinical data, including data of im-
munosuppression use/withdrawal from the patient charts in the colla-
borating transplant centers. The study was approved by the Ethics
Committees of the participating centers and conforms to the principles
of the Declaration of Helsinki.
2.2. HLA genotyping and antibody testing
We performed HLA-DP genotyping with IMMUCOR® MIA FORA
NGS HLA Typing kit on the Illumina MiSeq platform or with ONE
1st cohort: 
Clinical significance of HLA-DP 
antibodies?
14 patients with
- HLA-DP typed donor-recipient
- Isolated HLA-DP DSA in follow-up
- Histologic evaluation of post-
transplant biopsies
2nd cohort:
Occurrence of HLA-DP antibodies? 
HLAMatchmaker eplet analysis   
72 patients with 
- HLA-DP typed donor-recipient
- A failed kidney, back on the waiting list
- Negative pre-transplant HLA-class II 
screening
3rd cohort:
When do HLA-DP DSA lead to positive 
CDC or flow crossmatches? 
90 crossmatch results:
- 55 CDC-XM results
25 different donors and 42 different sera with isolated HLA-DP DSA
- 35 FCXM results
19 different donors and 10 different sera with isolated HLA-DP DSA
Fig. 1. Overview of the different questions with the respective cohorts to evaluate the clinical significance of HLA-DP mismatches and DSA in kidney transplantation.
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LAMBDA Inc. LinkSeq HLA Typing kit. HLA-DPA1 typing failed for 2
patients and 2 donors and no more material was available for retesting.
In these cases, the HLA-DPA1 typing was predicted on the basis of the
expected HLA-DPA1-DPB1 association [13].
The clinical outcome of patients with isolated HLA-DP DSA may
depend on the differential immunogenicity of the HLA-DPB1 mismatch
of the donor-recipient pair as defined by the group of K. Fleischhauer
[14–18]. Classification of HLA-DPB1 mismatches based on T-cell-epi-
tope groups (TCE groups) has been shown to identify mismatches that
can be tolerated (permissive) and those that will increase the risk of
complications (non-permissive) after unrelated donor hematopoietic
stem cell transplantation (HSCT) [14–18]. The DPB1 T-cell Epitope
Algorithm (www.ebi.ac.uk/ipd/imgt/hla/dpb.html. version 2.0) has
been used for the assignment of the TCE groups (permissive or non-
permissive HLA-DPB1) and has been assessed with regard to the clinical
outcome of patients with isolated HLA-DP DSA where only Host-versus-
Graft direction is relevant.
We performed HLA antibody evaluation with Immucor LIFECODES®
LifeScreen Deluxe kits. A positive screening for the presence of circu-
lating HLA antibodies was followed by HLA antibody identification
with LIFECODES® Luminex Single Antigen (LSA) kits. We performed
and interpreted all tests according to the manufacturer's instructions.
We reported Luminex Median Fluorescence Intensity (MFI) values of
HLA-DP DSA as the raw MFI and we made the sum of the MFI values
when DSA were present against the two HLA-DP alleles. When an HLA-
DP allele was not present on the Luminex beads, we calculated the
mean of the MFI values of the HLA-DP alleles with the shared eplet.
We defined HLA-DPA1 antibodies when the antibodies were directed
against a shared HLA-DPA1 eplet as suggested by the Luminex Single
Antigen analysis software MATCH IT! (111R,111 K,127P2,127L2) along
with the absence of antibodies against a shared antibody verified high-
risk eplet (84DEAV, 85GPM, 56A, 56E) for the corresponding HLA-DPB1.
2.3. Crossmatch tests
To evaluate the effect of HLA-DP-specific antibodies on the actual
crossmatch results, we performed B-cell CDC crossmatch tests. We
tested purified B-cells (spleen, peripheral blood (PB) or lymph nodes
(LN)) in a CDC crossmatch where positive reactions were defined as
reactions yielding a score of 2 (10–20% cell death) or greater using a
scale of 0–5. We performed 55 CDC-XM with patient sera exhibiting
isolated HLA-DP DSA.
We used a standard flowcytometric crossmatch method to analyze
the patient's sera and donor peripheral blood, spleen or lymph nodes
mononuclear cells by 3 color staining performed on a Beckman Coulter
Navios flow cytometer (CD3-APC, CD19-PE and goat (Fab’)2 anti-
human IgG-FITC) with a cutoff ≥ Negative Control Median Log
Channel +2SD. We performed 35 FCXM with patient sera exhibiting
isolated HLA-DP DSA.
We studied the correlation between HLA-DP DSA MFI values and
crossmatch results. To account for the potential impact of B cell source and
level of HLA expression [19,20], we classified crossmatch results according
to the donor cell type and HLA-DPB1 expression information based on the
linkage between the HLA-DPB1 expression marker rs9277534 and HLA-
DPB1 alleles as described by the group of E.W. Petersdorf [21,22].
2.4. HLAMatchmaker eplet analysis
We used HLAMatchmaker version 02 to determine the mismatched
eplets between donor and patient [23]. For HLA-DPB1, we have only
taken into account the so-called ‘antibody verified (Abv) eplets’, using
the information available on the website ‘www.epregistry.com.br’. For
HLA-DPA1, no Abv eplets are registered on this website. As an alter-
native, we have taken HLA-DPA1 eplets as suggested by the Luminex
Single Antigen analysis software MATCH IT! into consideration.
We considered eplets on HLA alleles with negative reactivity with LSA
as acceptable eplet mismatches and we eliminated these from the
Table 1
Patient characteristics.
L. Daniëls, et al. Transplant Immunology xxx (xxxx) xxxx
3
Ta
bl
e2
Cl
ini
ca
lo
ut
co
me
of
kid
ne
yt
ran
sp
lan
tp
ati
en
ts
wi
th
iso
lat
ed
HL
A-
DP
DS
A
(1
st
co
ho
rt,
N
=
14
).
To
ta
l
N
=
14
HL
A-
DP
all
ele
ag
ain
st
wh
ich
DS
A
ar
ed
ire
cte
d
(in
vo
lve
d
Ab
v
ep
let
s)
Th
er
ap
ya
tt
im
eo
f
tra
ns
pl
an
ta
tio
n
CD
C-
XM
wi
th
sp
lee
n
B-
ce
lls
Im
m
un
e-
pe
rm
iss
ive
HL
A-
DP
B1
1
HL
A-
DP
DS
A
M
FI
be
fo
re
tra
ns
pl
an
ta
tio
n
HL
A-
DP
M
FI
aft
er
tra
ns
pl
an
ta
tio
n2
An
tib
od
y-m
ed
iat
ed
re
jec
tio
n
oc
cu
rre
nc
e
(m
on
th
sa
fte
r
tra
ns
pl
an
ta
tio
n)
Gr
aft
fai
lu
re
(m
on
th
s
aft
er
tra
ns
pl
an
ta
tio
n)
Fo
llo
w-
Up
Ti
m
e
(m
on
th
sa
fte
r
tra
ns
pl
an
ta
tio
n)
Pa
tie
nt
1
DP
B1
*0
4:0
1(
No
Ab
v
ep
let
)
DP
B1
*0
4:0
1(
No
Ab
v
ep
let
)
Sta
nd
ard
7
+
AT
G
Ne
ga
tiv
e
Ye
s
36
2
36
2
Ne
ga
tiv
e
Ne
ga
tiv
e
No
No
44
Pa
tie
nt
2
DP
B1
*1
3:0
1(
84
DE
AV
)
DP
B1
*4
6:0
1(
57
D)
3
Sta
nd
ard
7
Ne
ga
tiv
e
Ye
s
38
8
89
4
Ne
ga
tiv
e
Ne
ga
tiv
e
No
Ye
s(
8)
(B
KV
11
)
8
Pa
tie
nt
3
DP
B1
*0
1:0
1(
84
DE
AV
)
Sta
nd
ard
7
Ne
ga
tiv
e
Ye
s
11
03
Ne
ga
tiv
e
No
No
25
Pa
tie
nt
4
DP
B1
*0
1:0
1(
84
DE
AV
)
Sta
nd
ard
7
Ne
ga
tiv
e
Ye
s
18
20
50
7
Ye
s(
1)
No
78
Pa
tie
nt
5
DP
B1
*0
1:0
1(
84
DE
AV
)
Sta
nd
ard
7
Ne
ga
tiv
e
Ye
s
31
41
19
18
Ye
s(
0.
2)
No
13
Pa
tie
nt
6
DP
B1
*1
4:0
1(
84
DE
AV
)
Sta
nd
ard
7
Ne
ga
tiv
e
No
(H
vG
)8
55
81
85
8
Ye
s(
3)
No
62
Pa
tie
nt
7
DP
B1
*1
04
:01
(8
4D
EA
V,
56
E)
4
Sta
nd
ard
7
+
AT
G
Ne
ga
tiv
e
No
(H
vG
)8
10
,43
6
No
ta
va
ila
ble
Ye
s(
0.
3)
Ye
s(
3)
3
Pa
tie
nt
8
DP
B1
*0
1:0
1(
84
DE
AV
)
DP
B1
*0
3:0
1(
84
DE
AV
,56
E)
5
DP
A1
*0
2:0
1
Sta
nd
ard
7
+
AT
G
Ne
ga
tiv
e
No
(H
vG
)8
49
85
40
06
Ne
ga
tiv
e
Ne
ga
tiv
e
No
No
65
Pa
tie
nt
9
DP
B1
*0
4:0
2(
85
GP
M
)
Sta
nd
ard
7
+
AT
G
Ne
ga
tiv
e
Ye
s
17
71
Ne
ga
tiv
e
No
No
3
Pa
tie
nt
10
DP
B1
*0
4:0
1(
85
GP
M
,56
A)
DP
B1
*0
4:0
1(
85
GP
M
,56
A)
Sta
nd
ard
7
Ne
ga
tiv
e
No
(G
vH
)9
61
34
61
34
37
24
37
24
Ye
s(
1)
Ye
s(
14
)
2
Pa
tie
nt
11
DP
B1
*0
4:0
1(
85
GP
M
)
DP
B1
*0
4:0
2(
85
GP
M
)
DP
A1
*0
1:0
3
Sta
nd
ard
7
Ne
ga
tiv
e
No
(G
vH
)9
12
,14
2
11
,60
4
13
48
15
52
No
No
80
Pa
tie
nt
12
DP
B1
*0
3:0
1(
56
E)
6
Sta
nd
ard
7
Po
sit
ive
No
(H
vG
)8
14
,05
0
63
44
Ye
s(
22
)
Ye
s(
29
)
29
Pa
tie
nt
13
DP
B1
*0
3:0
1(
57
D)
Sta
nd
ard
7
Ne
ga
tiv
e
No
(H
vG
)8
23
67
Ne
ga
tiv
e
No
No
8
Pa
tie
nt
14
DP
B1
*1
9:0
1D
PA
1*
02
:07
(1
27
P 2
)
Sta
nd
ard
7
N.
A.
No
(H
vG
)8
?1
0
13
,78
8
Ye
s(
19
8)
No
19
8
1
Pr
ed
ict
ed
im
mu
no
ge
nic
ity
of
th
eH
LA
-D
PB
1m
atc
hin
gf
or
th
ed
on
or
-re
ce
pto
rp
air
de
fin
ed
by
th
eg
ro
up
of
K.
Fle
isc
hh
au
er
[1
4–
18
].
2
MF
Iv
alu
eo
ft
he
las
ts
am
ple
(F
oll
ow
-U
pT
im
e)
or
th
el
as
ts
am
ple
be
for
eg
raf
tf
ail
ur
e.
3
Sim
ult
an
eo
us
pr
ese
nc
eo
f5
7D
DS
A
co
uld
no
tb
er
ule
do
ut
as
in
th
eL
um
ine
xa
ssa
yt
he
84
DE
AV
co
nt
ain
ing
be
ad
si
nc
lud
e5
7D
.
4
Sim
ult
an
eo
us
pr
ese
nc
eo
f5
6E
E
DS
A
co
uld
no
tb
er
ule
do
ut
as
in
th
eL
um
ine
xa
ssa
yt
he
56
E
co
nt
ain
ing
be
ad
si
nc
lud
e5
6E
E.
5
Sim
ult
an
eo
us
pr
ese
nc
eo
f9
6K
2
an
d3
5F
V
DS
A
co
uld
no
tb
er
ule
do
ut
as
in
th
eL
um
ine
xa
ssa
yt
he
56
E+
84
DE
AV
co
nt
ain
ing
be
ad
si
nc
lud
e9
6K
2
an
d3
5F
V.
6
Sim
ult
an
eo
us
pr
ese
nc
eo
f5
7D
DS
A
co
uld
no
tb
er
ule
do
ut
as
in
th
eL
um
ine
xa
ssa
yt
he
56
E
co
nt
ain
ing
be
ad
si
nc
lud
e5
7D
.
7
Sta
nd
ard
=
MM
F,
Ta
cro
lim
us
,s
ter
oid
s.
8
Hv
G=
Ho
st-
ve
rsu
s-G
raf
tr
ea
cti
on
.
9
Gv
H
=
Gr
aft
-ve
rsu
s-H
os
tr
ea
cti
on
.
10
LS
A
Cl
as
sI
Id
ata
no
ta
va
ila
ble
,b
ut
ma
le
wi
th
ou
tp
rev
iou
st
ran
sp
lan
tat
ion
s.
11
Gr
aft
fai
lur
ed
ue
to
BK
vir
us
.
L. Daniëls, et al. Transplant Immunology xxx (xxxx) xxxx
4
Table 3
HLAMatchmaker eplet analysis of the patients with a failed kidney, back on the waiting list (2nd cohort).
Mismatch between
donor and
recipient (Number
of donor-recipient
pairs)
Detection of post-
transplant HLA-
DP DSA (%)
Immunosuppressed
patient (%)
Presence of
highly expressed
HLA-DPB11
mismatch (%)
Other Abv eplet mismatches simultaneous present:
detection of post-transplant DSA
HLA-DPB1 Abv
eplet
mismatch
84DEAV (N=17)
No (N=3, 18%) No (N=0, 0%)
Yes (N=17,
100%)
• 35FV,56A,56E,56EE,57D,96K2,DPA1*02: No DSA• 96K2 (N=1): DSA
Yes (N=14, 82%) No (N=11, 79%)2 • 35FV,56E,56EE: No DSA• 57D: could not be discriminated from 84DEAV DSA as in
the Luminex assay the 84DEAV containing beads include
57D• 96K2: DSA (N=5), No DSA (N=8)
85GPM (N=10)
No (N=4, 40%) No (N=1, 25%) Yes (N=1, 25%) • 35FV,56A,56E,56EE: No DSA
Yes (N=6, 60%) No (N=6, 100%) Yes (N=0, 0%) • 35FV: DSA (N=1), No DSA (N=1)• 56A: DSA (N=1), No DSA (N=2)• 56E/56EE: DSA (N=2)• 96 K2: No DSA (N=1)
56A (N=11)
No (N=9, 82%) No (N=3,33%) Yes (N=3, 33%) • 84DEAV: No DSA• 85GPM: No DSA (N=1), DSA (N=2)• 96 K2: No DSA (N=1)
Yes (N=2, 18%) No (N=2100%) Yes (N=0, 0%) • 85GPM: DSA (N=1)
56E (N=17)
No (N=11, 65%) No (N=6,56%) Yes (N=4, 36%) • 84DEAV: No DSA (N=2), DSA (N=1)• 85GPM: No DSA (N=1)• 35FV: No DSA (N=8)• 56EE: No DSA (N=8), DSA (N=1)• 57D: No DSA (N=1); DSA (N=1)• 96 K2: No DSA (N=2), DSA (N=2)
Yes (N=6, 35%) No (N=6, 1000%) Yes (N=1, 17%) • 85GPM: DSA (N=2)• 35FV: No DSA (N=4), DSA (N=1)• 56EE: could not be discriminated from 56E DSA as in the
Luminex assay the 56E containing beads include 56EE
(N=5)• 57D: could not be discriminated from 56E DSA as in the
Luminex assay the 56E containing beads include 57D
(N=1)• 96 K2: No DSA (N=1)
HLA-DPA1
mismatch
DPA1*01 (N=4)
No (N=2, 50%) No (N=1, 50%) N.A. • 85GPM: No DSA (N=1), DSA (N=1)• 56E: No DSA (N=1)• 35FV: No DSA (N=1)
Yes (N=2, 50%)
(111 K,127L2)
No (N=2100%) N.A. • 85GPM: DSA (N=2)• 56E: DSA (N=2) (56EE: could not be discriminated from
56E DSA as in the Luminex assay the 56E containing beads
include 56EE)• 35FV: No DSA (N=1), DSA (N=1)• 96 K2: No DSA (N=1)
DPA1*02 (N=16)
No (N=9, 56%) No (N=4, 44%) N.A. • 84DEAV: No DSA (N=1), DSA (N=1)• 56A: No DSA (N=2)• 56E: DSA (N=1) (56EE: could not be discriminated from
56E DSA as in the Luminex assay the 56E containing beads
include 56EE)• 56EE: No DSA (N=2)• 35FV: No DSA (N=1)• 96 K2: No DSA (N=2)
Yes (N=7, 44%)
(111R,127P2)
No (N=7, 100%) N.A. • 84DEAV: DSA (N=6) (57D: could not be discriminated
from 56E DSA as in the Luminex assay the 56E containing
beads include 57D, N=1)• 85GPM: DSA (N=1)• 56A: No DSA (N=1)• 96 K2: No DSA (N=4), DSA (N=2)
1 HLA-DPB1 expression information based on the linkage between the HLA-DPB1 expression marker rs9277534 and HLA-DPB1 alleles as described by the group of
EW Petersdorf [21,22].
2 One case with presence of 96K2 DSA instead of 84DEAV DSA.
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analysis. We analyzed the remaining mismatched eplets on HLA alleles
with positive reactivity to explain the antibody reactivity patterns. We
performed a tail analysis on the Luminex Single Antigen data with r va-
lues of 1, only eplets with no false-positive or -negative reactions are
included.
3. Results
3.1 Clinical outcome of kidney transplant patients with isolated
HLA-DP DSA
In a cohort of 1737 kidney transplant recipients, we identified 14
HLA-DP typed donor-recipient pairs with isolated HLA-DP DSA in
follow-up (Fig. 1 and Table 1: 1st cohort): 13 patients were transplanted
(deceased donor) with pretransplant HLA-DP DSA and only 1 patient
developed isolated HLA-DP DSA post-transplant (Table 2). Twelve of
the 13 patients with pretransplant HLA-DP DSA had a history of pre-
vious transplantation and for the other patient pregnancy was the likely
cause of the immunization. We observed antibody-mediated rejection
(AMR) in 6 out of the 13 patients (46%) with pretransplant HLA-DP
DSA. The DSA that were involved in these cases of AMR were directed
against the mismatched eplet 84DEAV, against the mismatched eplets
85GPM+56A and against the mismatched eplet 56E.
We had only one case with isolated HLA-DP DSA first detected post-
transplant, with unclear temporal relation to the detection of chronic
AMR as no HLA-DP antibody detection was performed before histologic
evaluation of the biopsy. The DSA were directed against HLA-
DPA1*02:07DPB1*19:01 with an antibody reactivity pattern against
the mismatched 127P2 eplet. As there were no antibodies detected
against a shared high-risk eplet of HLA-DPB1*19:01, we assumed the
presence of HLA-DPA1 DSA.
3.2 HLA eplet mismatches and HLA-DP antibody formation
Next, we evaluated the relationship between HLA-DP eplet mis-
match and HLA-DP antibody formation in patients with a failed kidney
transplant, back on the waiting list for a repeat transplantation (Fig. 1
and Table 1: 2nd cohort). HLA-DP DSA were present in 25 (35%) out of
the 72 failed kidney transplants.
With HLAMatchmaker eplet analysis (Table 3) we observed that the
induction of HLA-DP DSA was associated with the presence of at least
one of the 4 high-risk HLA-DPB1 eplet mismatches 84DEAV (52%),
85GPM (12%), 56E (16%), 56A (4%), 85GPM+56A (4%) and
85GPM+56E (8%), except for one case that was associated with 96K2
eplet. Out of the 72 cases 55 (76%) had 1 or 2 of these high-risk eplet
mismatches. HLA-DP DSA developed after graft failure and cessation of
immunosuppression in all cases with a 84DEAV eplet mismatch (100%),
in 6 out of 7 with a 85GPM eplet mismatch (86%), in 2 out of 5 with a
56A eplet mismatch (40%) and in 6 out of 12 with a 56E eplet mismatch
(50%). In all the cases with HLA-DP DSA other DSA were also present.
In this case series, a mismatched 84DEAV eplet was only present on
HLA-DPB1 alleles known to have a high expression [21,22]. In the
group of HLA-DP DSA, 85GPM and 56A mismatch eplets were present
on low expressed HLA-DPB1 [21,22] alleles and 56E mismatch eplet on
both high and low expressed HLA-DPB1 [21,22] alleles. In the group
with anti-56E DSA, the antibodies were detectable for a short period of
time and with low MFI values in 3 out of 6 cases.
We also observed HLA-DP antibodies against other eplets (35FV,
56EE, 57D and 96K2), in most of the cases in combination with anti-
84DEAV, anti-85GPM, anti-56A, or anti-56E DSA.
Twenty cases with an HLA-DPA1 mismatch were present in our
series of 72 donor-recipient pairs. Four had an HLA-DPA1*01 mismatch
and 16 an HLA-DPA1*02 mismatch. In the HLA-DPA1*01 mismatch
group, 2 out of 4 patients (50%) developed HLA-DPA1 DSA against the
mismatched eplet 111 K or 127 L2. In the HLA-DPA1*02 mismatch
group, 7 out of 16 patients (44%) developed HLA-DPA1 DSA against the
mismatched eplet 111R or 127P2. In the serum of all patients with HLA-
DPA1 DSA, we also detected DSA against HLA-DPB1. In all patients
with HLA-DPA1*01 DSA, we detected anti-85GPM or anti-56E DSA. In
all patients with HLA-DPA1*02 DSA, we observed anti-84DEAV DSA or
anti-85GPM DSA.
3.3 When do HLA-DP DSA lead to positive CDC or flowcytometric
crossmatches?
Among the 90 crossmatch results (Fig. 2), CDC and flowcytometric
crossmatches were negative when the MFI values of HLA-DP DSA were
below 2000. CDC crossmatches were also negative when the MFI values
of HLA-DP DSA were below 10,000.
When the MFI values of HLA-DP DSA were above 10,000 we ob-
served both positive (N=9, 41%) and negative (N=13, 59%) CDC
crossmatch results. We observed positive CDC crossmatch results with 5
crossmatches in the presence of DSA against high expressed HLA-DPB1
and with 4 crossmatches in the presence of DSA against low expressed
HLA-DPB1. We observed negative CDC crossmatch results in 13 cases,
of which 6 cases with HLA-DP DSA MFI>20,000, including 2 cases
with HLA-DPA1 DSA, 2 cases whereby the distinction could not be
made between HLA-DPA1 DSA (DPA1*01:03) and HLA-DPB1 DSA
(DPB1*04:01/DPB1*04:02/DPB1*05:01) and 2 cases with DSA prob-
ably against a non-high-risk eplet.
When the MFI values of HLA-DP DSA were above 2000, we observed
both negative (N=26, 90%) and positive (N=3, 10%) flowcytometric
crossmatch results. With HLA-DP DSA MFI 2000–5000 we observed two
positive FCXM results, both with DSA against high expressed HLA-
DPB1. We observed 1 positive FCXM with DSA against low expressed
HLA-DPB1 with cumulative MFI of 18,676. We observed 15 negative
flowcytometric crossmatches with HLA-DPA1 DSA (MFI range 2000 –
>20,000). We also observed negative crossmatches in 6 cases with DSA
against high expressed HLA-DPB1 (MFI range 2000–5000), in 1 case
with DSA against low expressed HLA-DPB1 (MFI 2800) and in 4 cases
with probably false positive DSA (MFI range 2000–10,000) (anti-HLA-
DPB1*04:01DPA1*01:03 and anti-HLA-DPB1*02:01 DSA were also
tested with One Lambda Luminex Single Antigen assay and not con-
firmed by this second vendor).
To further evaluate the negative crossmatch results in cases with
HLA-DPA1 antibodies with high MFI up to 20,000, we next excluded
false positive HLA-DPA1 antibody Luminex by confirming the HLA-
DPA1 antibodies with a second vendor (Onelambda). In addition, we
performed an adsorption analysis according to the protocol of El-Awar
et al. [24], using a donor-recipient serum combination with anti-HLA-
DPA1*01:03 DSA and anti-HLA-A1 DSA. The Luminex pattern before
and after adsorption was similar for HLA-DPA1*01:03 but became ne-
gative for anti-HLA-A1. These results confirmed the negative cross-
match results despite the high HLA-DPA1 DSA.
4. Discussion
The presence of isolated HLA-DP antibodies is a rare event and
therefore the association of HLA-DP DSA with antibody-mediated injury
and allograft failure is difficult to assess. In this case series, we have
observed that HLA-DP antibodies may appear after kidney transplan-
tation and pregnancy. We observed AMR in 6 out of the 13 patients
(46%) with pretransplant isolated HLA-DP DSA, directed against
84DEAV, 85GPM+56A or 56E eplet mismatches. We observed no
correlation with the predicted immunogenicity of the HLA-DPB1
matching for the donor-receptor pair as defined by the group of K.
Fleischhauer [14–18] showing a differential immunogenicity for the
cellular versus the humoral immune response. Between 2008 and 2018
we have identified only 3 cases with HLA-DP DSA detected during
follow-up after transplantation, of which there was only 1 case with
isolated HLA-DP DSA with an unclear relation to the detection of
chronic AMR. Different reports have shown that HLA-DP mismatches
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between donor and recipient do not influence the outcome of first
kidney transplants, but may have an impact on retransplants [3,4,25].
The hypothesis is that graft injury is necessary for the HLA-DP anti-
bodies to develop and makes them less likely to be the primary cause of
deteriorating graft function [3]. In our case we could not make a dis-
tinction between HLA-DP DSA as cause of AMR or acute rejection as
cause of HLA-DP DSA development. The clinical relevance of post-
transplant de novo HLA-DP DSA in follow-up is still unclear as the
presence of isolated HLA-DP DSA is a rare event. There is a possibility
that HLA-DP DSA are as important as HLA-DQ, because they are also
upregulated upon inflammation [26,27].
The eplets 84DEAV, 85GPM, 56A and 56E, against which antibodies
are detected in the AMR clinical cases, were also the high-risk
HLAMatchmaker eplet mismatches in the study on the incidence of
HLA-DP antibodies after a failed kidney graft. Seventy-six % of the
retransplant candidates had an important HLA-DP mismatch, as they
are associated with 1 or 2 of the high-risk eplets and 25 out of 35 pa-
tients (71%) with a high-risk HLA-DP eplet mismatch developed HLA-
DP DSA if immunosuppression was discontinued, all combined with
other HLA-DSA. We also observed HLA-DP antibodies against other
eplets (35FV, 56EE, 57D and 96K2), most in combination with anti-
84DEAV, anti-85GPM, anti-56A, or anti-56E DSA, except for 2 cases.
One case had only anti-96 K2 DSA but with the presence of 84DEAV
eplet mismatch and one other case had only anti-56EE DSA but also
with the presence of 56E mismatch, which may indicate epitope
spreading or false positivity of certain bead reactions in the Luminex
assay. So, although there is a certain risk of developing HLA-DP DSA
(35% of retransplant candidate cases, 2nd cohort), the chance of iso-
lated HLA-DP DSA is very low (0% of retransplant candidate cases, 2nd
cohort).
In our clinical case cohort, we observed AMR with pretransplant
isolated HLA-DP DSA with an MFI of 1820 and above. Unfortunately,
no FCXM data and complement binding Luminex assays ware available
in this cohort for further risk stratification. Correlation analysis be-
tween isolated HLA-DP DSA MFI and CDC and flowcytometric cross-
matches (N=90) illustrated that HLA-DP DSA with MFI above 10,000
generated both positive (N=9, 41%) and negative (N=13, 59%) CDC
crossmatch results and HLA-DP DSA with MFI above 2000 generated
both positive (N=26, 90%) and negative (N=3, 10%) flowcytometric
crossmatch results. The difference in positivity of the crossmatches
could be explained by false positivity of the Luminex assay, MFI values
not providing true antibody strength, the wrong assessment of HLA-DP
DSA (a small number of HLA-DP alleles that are covered by the Luminex
beads) and may be related to the immunodominance of the eplet and
HLA-DPA1 DSA. We observed negative crossmatch results in cases with
HLA-DPA1 DSA with high MFI up to 20,000. The HLA-DPA1 antibody
patterns that we have observed were directed against the eplets
111 K,111R,127L2,127P2. None of these eplets were registered in the
HLA epitope registry (www.epregistry.com.br/) as antibody verified,
although they were located at the surface in the alpha 2 domain ac-
cording to 3D modeling (www.ncbi.nlm.nih.gov/Structure/CN3D/
cn3d.shtml) of the crystal structures 3WEX (HLA-
Fig. 2. CDC and flowcytometric crossmatch results (3rd cohort).
The upper charts present 55 CDC-XM results and are divided into 3 graphs: 1 graph for XM results with DSA (Y-axis: MFI values) against high expressed HLA-DPB1 (X-
axis: the different HLA-DP alleles), 1 graph for XM results with DSA (Y-axis: MFI values) against low expressed HLA-DPB1 (X-axis: the different HLA-DP alleles) and 1
graph for XM results with DSA (Y-axis: MFI values) against HLA-DPA1 (X-axis: different HLA-DP alleles). Each bar presents a different XM result between a patient
serum with isolated HLA-DP DSA and donor purified B-cells (spleen, peripheral blood (PB) or lymph nodes (LN)). The bottom charts present 35 FCXM results and
divided in 3 graphs: 1 graph for XM results with DSA (Y-axis: MFI values) against high expressed HLA-DPB1 (X-axis: the different HLA-DP alleles), 1 graph for XM
results with DSA (Y-axis: MFI values) against low expressed HLA-DPB1 (X-axis: the different HLA-DP alleles) and 1 graph for XM results with DSA (Y-axis: MFI values)
against HLA-DPA1 (X-axis: different HLA-DP alleles). Each bar presents a different XM result between a patient serum with isolated HLA-DP DSA and donor purified
B-cells (spleen or peripheral blood (PB)). The different colors of the bars are as follows:
Negative XM result:
Positive XM result:
Negative XM result, false positive Luminex HLA-DP DSA:
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DPA1*02:02DPB1*05:01), 4P5M (HLA-DPA1*01:03DPB1*02:01) and
4P57 (HLA-DPA1*01:03DPB1*105:01) as shown in Fig. 3. Possible
explanations for negative crossmatches and positive Luminex Single
Antigen assays could be a weak affinity of the antibodies for these HLA-
DPA1 eplets or binding of the antibodies to denatured HLA-DP mole-
cules on the surface of the Luminex beads. Gorga et al. [28] have indeed
shown that HLA-DP molecules revealed several properties not found
with HLA-DR and HLA-DQ and Young et al. [29] have shown that the
binding of a certain HLA-DP antibody is influenced by the associations
between the alpha and beta chain. Information regarding HLA-DP an-
tibodies must be captured to represent the complete molecule, a com-
bination of both the alpha and beta chains as it is expressed on the cell
surface and not on the Luminex beads. Further studies are warranted to
further characterize the clinical significance of HLA-DPA1.
In our series, we could not observe an influence of HLA-DP ex-
pression on crossmatch results or HLA-DP DSA formation. In all our
cases, the 84DEAV eplet mismatch was only present on high expressed
HLA-DP alleles and this eplet mismatch generated HLA-DP antibodies in
100% of the cases when immunosuppression was discontinued. This
could give the false impression that HLA-DP expression is the leading
cause of DSA formation but this observation was not confirmed with the
other eplets. HLA-DP expression could still play a role as we did not
perform any HLA-DP expression analyses ourselves and our conclusions
were only based on the linkage between the HLA-DPB expression
marker rs9277534 and HLA-DPB1 alleles [21,22]. In addition, HLA
expression may also have been impacted by extrinsic factors such as
disease, infection, age and medications [19].
Another limitation of our series is the selection bias of the different
cohorts, as we only included donor-recipient pairs whose HLA-DP type
was known. HLA-DP typing was only routinely performed when HLA-
DP antibodies were present and in the context of a large retrospective
study an additional 1000 donor-patient pairs were HLA-DP typed with
NGS [30]. To perform a correct HLAMatchmaker analysis, an additional
criterion was that the HLA class II antibody screening was negative
before transplantation. This also means that we could have missed
pretransplant isolated HLA-DP antibodies as Luminex Single Antigen
Class II testing was not performed for 5 retransplant patients and 20
women who might have been immunized by the previous transplanta-
tion or pregnancies.
In conclusion, isolated HLA-DP DSA are rare, yet constitute a sig-
nificant risk for antibody-mediated rejection. We identified high-risk
eplet mismatches that can lead to HLA-DP DSA formation. We therefore
recommend HLA-DP typing to perform HLA-DP DSA analysis before
transplantation. The presence of HLA-DP DSA with high MFI was not
always correlated with positive crossmatch results. Further studies are
warranted to further characterize the clinical significance of the nega-
tive crossmatch results with isolated HLA-DP DSA with high MFI.
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